Xenon Pharmaceuticals Inc. (XENE) Upgraded to Hold by Zacks Investment Research
According to Zacks, “Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. “
XENE has been the topic of a number of other reports. Guggenheim assumed coverage on Xenon Pharmaceuticals in a research report on Monday, September 26th. They issued a buy rating and a $20.00 price objective on the stock. Canaccord Genuity restated a buy rating and issued a $16.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 5th.
Xenon Pharmaceuticals (NASDAQ:XENE) traded up 0.36% on Thursday, reaching $8.28. The company had a trading volume of 102,526 shares. The firm has a 50 day moving average price of $7.96 and a 200-day moving average price of $7.28. The stock’s market capitalization is $119.45 million. Xenon Pharmaceuticals has a 12 month low of $5.65 and a 12 month high of $9.93.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.06. Xenon Pharmaceuticals had a negative return on equity of 28.85% and a negative net margin of 199.68%. Analysts forecast that Xenon Pharmaceuticals will post ($1.55) earnings per share for the current fiscal year.
In other Xenon Pharmaceuticals news, Director Frank A. Holler sold 11,938 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, August 19th. The stock was sold at an average price of $7.65, for a total transaction of $91,325.70. Following the transaction, the director now directly owns 145,869 shares in the company, valued at $1,115,897.85. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Frank A. Holler sold 18,062 shares of Xenon Pharmaceuticals stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $7.93, for a total value of $143,231.66. Following the transaction, the director now owns 169,006 shares in the company, valued at $1,340,217.58. The disclosure for this sale can be found here. Company insiders own 11.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Opaleye Management Inc. raised its position in Xenon Pharmaceuticals by 33.3% in the first quarter. Opaleye Management Inc. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $2,796,000 after buying an additional 100,000 shares in the last quarter. Perceptive Advisors LLC raised its position in Xenon Pharmaceuticals by 110.3% in the second quarter. Perceptive Advisors LLC now owns 432,800 shares of the biopharmaceutical company’s stock valued at $2,553,000 after buying an additional 227,000 shares in the last quarter. Finally, BVF Inc. IL raised its position in Xenon Pharmaceuticals by 57.7% in the first quarter. BVF Inc. IL now owns 1,775,572 shares of the biopharmaceutical company’s stock valued at $12,411,000 after buying an additional 650,000 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies).
Receive News & Stock Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.